Life Sciences

  • May 21, 2026

    Vape Sellers Say Pa. E-Cig Law Usurps FDA Authority

    Vape companies are looking to stop a Pennsylvania law that would effectively ban most e-cigarettes, claiming in a federal lawsuit that the statute is unconstitutional, would destroy roughly $2 million of their inventory and targets products that federal regulators say helps smokers quit.

  • May 21, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Virginia's governor vetoed legislation to establish adult-use marijuana sales, keeping the state in cannabis legal limbo; Illinois lawmakers introduced legislation to rein in hemp products, aligning state policy with an upcoming shift in federal law; and Louisiana lawmakers sent a bill to the governor that would allow terminally ill patients to access medical marijuana in healthcare facilities. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • May 21, 2026

    BigLaw Deals Scandal Puts Boston Back On White Collar Map

    A sweeping insider trading case involving information stolen from BigLaw firms shows a return to bread-and-butter white collar enforcement for Boston federal prosecutors and provides a morale lift in an office that has seen shifting priorities and staff turnover since the signature "Varsity Blues" takedown in 2019, veteran prosecutors told Law360.

  • May 21, 2026

    Immunity Bid Can't Stop Discovery In THC Abuse Registry Suit

    There's little chance that the Idaho state health director can ditch litigation by mothers challenging the automatic placement of women on the child abuse registry for prenatal THC use, a federal judge said after taking a "preliminary peek" at the state's pending motion to dismiss.

  • May 21, 2026

    Amgen Wants To Preserve Right To Seek Double Tax Relief

    Drugmaker Amgen wants to preserve its right to seek a refund for tax years 2010 through 2015 if the IRS "persists" in taking a position inconsistent with the agency's own arguments pertaining to those years in its audit of 2016 to 2018, the company told the U.S. Tax Court.

  • May 21, 2026

    Texas Comptroller Tells 5th Circ. To Toss E-Cig Ban Suit

    The acting comptroller for Texas is asking the Fifth Circuit to overturn an order allowing vape companies and a trade association to pursue a suit challenging a state law banning e-cigarette products that use liquids from China and other "adversaries," saying the comptroller is entitled to sovereign immunity.

  • May 21, 2026

    Fed. Circ. Backs Lupin Win In Generic Kidney Drug Case

    The Federal Circuit on Thursday affirmed a Delaware federal judge's ruling that Indian generic-drug maker Lupin's version of the kidney disease drug Jynarque does not infringe two patents held by Japanese rival Otsuka.

  • May 21, 2026

    AmeriHealth Unit, PBM Sued Over Prescription Claim Fees

    Two Philadelphia pharmacies have filed a proposed class action against AmeriHealth Caritas Health Plan and its in-house pharmacy benefits manager, PerformRx LLC, claiming the companies violate Pennsylvania law by not disclosing "transmission fees" at the time a claim is run through the pharmacies' computers, according to a complaint removed to federal court.

  • May 21, 2026

    Zantac Cases To Proceed During Appeal Of Recusal Denial

    The Philadelphia judge overseeing the city's Zantac cancer mass tort will not halt proceedings while Keller Postman LLC appeals his refusal to recuse himself from the litigation on the basis that his wife works at Blank Rome LLP, which represents a pharmaceutical company in one of the 550 cases.

  • May 20, 2026

    Prof. Hired By J&J In 1970s Found Asbestos In Talc, Jury Told

    A former Johnson & Johnson toxicologist could not find evidence his employer turned over a report to the U.S. Food and Drug Administration that "unmistakably" found asbestos in the company's talc, according to a video deposition shown Wednesday to a California jury considering bellwether claims over three women's deadly ovarian cancer.

  • May 20, 2026

    DOJ, Drugmakers Spar After Justices Snub 6 Negotiation Suits

    The U.S. Department of Justice is trying to have it both ways in drug pricing litigation, telling the U.S. Supreme Court not to intervene before additional circuits decide pending challenges and then using this week's nonintervention as ammunition against those challenges, drugmakers are arguing at appeals courts.

  • May 20, 2026

    Minnesota Jury Awards $10.2M In Talc Mesothelioma Trial

    A Minnesota state jury has delivered a $10.2 million verdict to a married couple in their suit against Vi-Jon LLC and the makers of other talc products like Johnson & Johnson and Gold Bond in which they alleged the 45-year-old husband's mesothelioma was caused by exposure to body powder products.

  • May 20, 2026

    2nd Circ. Skeptical Of Bid To Boost Drug Royalty Award

    A Second Circuit panel appeared unsympathetic during oral arguments on Wednesday to Acorda Therapeutics Inc.'s assertion that it should be awarded nearly $66 million beyond the $16.5 million it won in a multiple sclerosis drug dispute, with one judge remarking that the company is "kind of in the soup" because it chose arbitration.

  • May 20, 2026

    1st Circ. Allows Transfer Of RI Youth Care Info To Texas Court

    The First Circuit declined to halt a Texas federal court's order requiring a Rhode Island hospital to hand over records detailing its provision of gender-affirming care to minors, finding a Rhode Island agency failed to demonstrate that doing so would cause children in the state irreparable harm.

  • May 20, 2026

    Refusing Sandoz Parent Dismissal 'Clear Error,' Court Told

    Sandoz's Swiss parent company wants a Pennsylvania federal judge to rethink her decision forcing it to face generic drug price-fixing claims from major employers like General Motors, arguing the court "conflates" Novartis AG with Sandoz AG, which was spun off in 2023.

  • May 20, 2026

    Eli Lilly Loses Bid To Limit Ex-FDA Chief's Take In GLP-1 MDL

    A Pennsylvania federal judge said Eli Lilly & Co. and plaintiffs in multidistrict litigation accusing it of downplaying side effects of weight loss drugs were talking past each other in a dispute over expert testimony, denying Eli Lilly's bid to limit the opinions of the plaintiffs' expert to those disclosed in his report.

  • May 20, 2026

    Tiversa Escapes LabMD's Final Defamation Claims

    A defunct cancer screening lab cannot show that a cybersecurity firm CEO had "actual malice" when he made allegedly defamatory statements about a file of private health info being "exposed," "leaked" and "publicly available" nearly 20 years ago, a federal magistrate ruled in dismissing a long-running lawsuit Tuesday.

  • May 20, 2026

    Eli Lilly Paying Up To $202M In Genetic Medicine Deal

    Eli Lilly and Co. has agreed to acquire privately held Engage Biologics Inc., which is developing a delivery technology for genetic medicines, in a deal worth up to $202 million, Cooley LLP-advised Engage announced Wednesday.

  • May 20, 2026

    Intellia Drops Counterclaims In Gene-Editing Patent Case

    Intellia Therapeutics Inc. has agreed to drop a set of claims it asserted in a Delaware federal suit brought by BlueAllele, which accused it of infringing three gene-editing patents to bring in $100 million in a deal with Regeneron Pharmaceuticals.

  • May 20, 2026

    Squires Institutes 5 Patent Reviews, Rejects 7 Others

    U.S. Patent and Trademark Office Director John Squires on Tuesday granted five requests for review of patents under the America Invents Act while turning down seven other petitions.

  • May 20, 2026

    FTC 'Close' To Final PBM Insulin Price Deal With OptumRx

    Federal Trade Commission staffers have signaled that they're near a settlement with UnitedHealth Group Inc.'s OptumRx that would close out the agency's in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes.

  • May 19, 2026

    Quinn Emanuel Owes More Sanctions In Guardant Fight

    Quinn Emanuel and its team representing medical testing company Natera will shoulder further sanctions on top of the $3 million already imposed over the firm's misrepresentations concerning an expert witness in Guardant Health's false advertising case, a California federal judge ruled Tuesday.

  • May 19, 2026

    Monsanto To Pay Mich., RI Up To $302M Over PCB Pollution

    Monsanto has reached multimillion-dollar deals with Michigan and Rhode Island to end claims that the company contaminated waterways and natural resources with polychlorinated biphenyls, agreeing to pay the states as much as $240 million and $62 million, respectively, with most of that money contingent on how the company recovers from separate lawsuits.

  • May 19, 2026

    Toxicologist Denies J&J Wanted To 'Control' Talc Study

    A former Johnson & Johnson toxicologist denied the company controlled a 1970s study of talc miners by insisting "you do not control" people like the professor behind the study, in a video deposition shown Tuesday to a California jury considering bellwether claims the company's talc products caused deadly ovarian cancer in three women.

  • May 19, 2026

    Calif. Urges 9th Circ. To Revive Pay-For-Delay Restrictions

    California urged a Ninth Circuit panel Tuesday to find a Golden State law that bans drugmakers from cutting deals out of state that pay to delay generics competition doesn't violate the U.S. Constitution, arguing that ruling otherwise could jeopardize many longstanding state laws that regulate out-of-state conduct.

Expert Analysis

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

  • 2025's Most Notable State AG Activity By The Numbers

    Author Photo

    State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.

  • Opinion

    The Case For Emulating, Not Dividing, The Ninth Circuit

    Author Photo

    Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.

  • How Rule 16.1 Streamlines And Validates Mass Tort Litigation

    Author Photo

    The new Rule 16.1 of the Federal Rules of Civil Procedure not only serves a practical purpose by endorsing early, structured case management and dispositive motion practice in multidistrict litigation, but also explicitly affirms the importance of MDL practice in the justice system, says Rocco Strangio at Milestone.

  • How 11th Circ.'s Zafirov Decision Could Upend Qui Tam Cases

    Author Photo

    Oral argument before the Eleventh Circuit last month in U.S. ex rel. Zafirov v. Florida Medical Associates suggests that the court may affirm a lower court's opinion that the qui tam provisions of the False Claims Act are unconstitutional — which could wreak havoc on pending and future qui tam cases, say attorneys at Morgan Lewis.

  • Key Trends For Life Sciences Cos. To Watch In 2026

    Author Photo

    Following a year of drastic change at the U.S. Food and Drug Administration, two themes are likely to drive the coming year — a commitment to lowering the cost of drugs and an inherent tension between the priorities of the health agencies and the broader administration, say attorneys at Sheppard Mullin.

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.